Our CEO, John Lepore, joins colleagues at the Flagship Pioneering Studio to share what’s ahead for ProFound as we pioneer the expanded human proteome to reveal a universe of new medicines. #FlagshipJPM #JPM24

We’re celebrating the profound impact of #WomenInScience who are paving the way for the next generation of leaders in #STEM. At ProFound, we celebrate the women pioneers in our leadership and across our team. #February11 #IDWGIS

We’re proud to be #FlagshipFounded and are excited to spotlight #WomenInScience, including our very own #IDWGS panel participant Vini Mani, our Chief Innovation Officer! Join us in celebrating women in #STEM as we help shape the future of #innovation in #biotech and science.

In Part 6 of #ScripsAsks “What does 2024 hold for #biopharma?”, our CEO, John Lepore, discusses new potential treatments for chronic diseases within the #DarkProteome. Learn more about how we’re illuminating novel proteins in this Scrip, Citeline Commercial article: brnw.ch/21wH9HS

Happy #InternationalWomensDay! Today we're celebrating women's achievements around the world. Our President, Kala Subramanian, shares how we #InspireInclusion at ProFound Tx as we pioneer the #darkproteome to unlock a new universe of first-in-class medicines.

Congratulations Flagship Pioneering on being named one of the world’s most innovative companies by Fast Company 3 years running! We're proud to be #FlagshipFounded as we pioneer the #darkproteome to take #BiggerLeaps for patients.

Our ProFoundry™ Platform is illuminating the #DarkProteome, unveiling a new universe of novel drugs and drug targets with first-in-class potential. Learn more about our unique approach here: brnw.ch/21wIj8q

It’s #NationalDNADay! The human genome encodes an unexplored universe of proteins known as the #DarkProteome. We are uncovering the therapeutic potential of the expanded proteome to bring first-in-class medicines to patients. Learn more: profoundtx.com/our-science

The ProFoundry™ Atlas catalogs novel proteins and predicts their function and therapeutic relevance. This data-rich engine enables us to mine the #DarkProteome for novel proteins most likely to lead to first-in-class medicines for patients. Learn more: brnw.ch/21wJvqO

Our ProFoundry™ Platform has unveiled new proteins within the #ExpandedProteome spanning many functionalities of therapeutic interest. We’re aiming to develop first-in-class medicines for unmet patient needs. Learn more: bit.ly/4aV1Klr

In partnership with Flagship Pioneering we’re thrilled to announce a collaboration with @Pfizer using our ProFoundry™ Platform to conduct foundational research to identify potential next-generation first-in-class therapies for the treatment of #obesity More: profoundtx.com/news-and-event…

Mark your calendars for the upcoming Longwood Healthcare Leaders #SpringMIT conference where our CEO, John Lepore, and other #biotech industry innovators will be discussing the journey of translating science into first-in-class medicines. Register here: bit.ly/3V9vxkE

Check out this article from Drew Armstrong @Endpts showcasing our first collaboration with Flagship Pioneering's Pioneering Medicines & @Pfizer harnessing our ProFoundry™ Platform to identify first-in-class medicines for #obesity treatment. Read the article here: bit.ly/4b5UhAh

We’re pioneering the #ExpandedProteome by identifying open reading frames that encode functional proteins outside of the confines of the Human Genome Project. Learn about how we’re executing our vision of expanding therapeutic possibilities for patients: bit.ly/4bDe0aZ

In the latest episode of the BioProcess Online #BusinessOfBiotech podcast, our CEO, John Lepore, dives into our mission of pioneering the #ExpandedProteome and bringing new therapeutic possibilities to patients worldwide. Listen to the episode here: bit.ly/3A7deWv

We’re thrilled to announce FierceBiotech has selected us as a 2024 #Fierce15 #biotech company! This year we have rapidly advanced our ProFoundry™ Platform identifying novel proteins with the possibility to bring new therapeutic options to patients. More: bit.ly/3YwXMgt

Want to learn about proteins hidden within our genome? Cast your vote for “The Secret Life of DNA” panel @SXSW 2025, diving into the mysteries of DNA & how new genetic knowledge is the future of medicine. #PanelPicker voting is open until August 18th: panelpicker.sxsw.com/vote/150133

Our Chief Innovation Officer Vinidhra Mani has been named a 2024 Boston Business Journal 40 under 40 honoree! Vini’s leadership & contributions since our founding have been invaluable to our rapid growth & success illuminating the #ExpandedProteome. See the full list: bit.ly/3MpEm5X

📆 Mark your calendars! Our CEO, John Lepore, is moderating a panel at the BioCentury Grand Rounds R&D conference. Listen in on the discussion to learn about the role of causal #biology in achieving preclinical validation. More: bit.ly/3MCeNhZ #BioCenturyGrandRounds

Next week, our CEO, John Lepore, is joining a panel at the @MBGInnovation World Medical Innovation Forum. Stop by to learn about new innovations being developed to address the many patient needs that remain unmet. #WMIF2024